TELA Bio Inc
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying TELA Bio's stock with a target price of $14.2, showing strong growth potential.
Financial Health
TELA Bio Inc is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TELA
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial Traction
Growing product sales and surgeon adoption could drive revenue, though early commercial profiles may be uneven and subject to reimbursement hurdles.
Clinical Evidence
Clinical studies and regulatory milestones can validate technology and expand use, but outcomes and approvals are uncertain and may affect valuation.
Competitive Market
There’s clear demand for improved soft‑tissue repair solutions globally, yet competition from established device makers and pricing pressures remain important risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
